SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of federal securities law violations related to the safety of its product ELEVIDYS, which has been linked to patient deaths and adverse events [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Sarepta, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][12]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Safety Concerns and Stock Price Impact - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, failing to disclose significant safety risks and adverse events [5]. - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [6]. - On April 4, 2025, after disclosing regulatory scrutiny and halting recruitment in clinical studies, the stock price dropped by $4.18 per share, or 7.13%, to close at $54.43 [8]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [10]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into acute liver failure risks associated with ELEVIDYS, resulting in a further stock price drop of $1.52 per share, or 8.01%, to close at $17.46 [10][11].